News | May 16, 2025
Piramal Pharma reports Q4 FY25 consolidated net profit of Rs. 153.50 Cr
The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025
Ideal for extreme dry skin and hyperkeratotic conditions such as psoriasis and ichthyosis, Ureaderm offers the next step in evidence-based, effective skin hydration
EBITDA before special items decreases to €4.08 billion (7.4%)
_256_384.jpg)
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
Haloperidol Decanoate Injection indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy
The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025
The inspection conducted from December 16, 2024 to December 20, 2024 by the Brazil Health Regulatory Agency (ANVISA)
The Protect VL project was born out of a vision to reduce the environmental footprint of medical devices
ISPP will analyze health systems across states, identifying scalable models and actionable insights to strengthen India's healthcare delivery
Subscribe To Our Newsletter & Stay Updated
